Tissue cross-reactivity study of a human antibody
Ended Awarded Last action
- Contract number
- 75N91021F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $106,343
Award facts
- Opportunity
-
- TORP20210125 Solicitation number
- Contract value 37% obligated
-
- $106,343.10 Current, with exercised options
- $286,117.10 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21701, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,195 | |
| Original award | $107,538 |
About this award
The National Cancer Institute issued a delivery order to Sri International on April 9, 2021, under the Toxicology of Drugs Developed for Cancer Patients IDIQ for a tissue cross-reactivity study of a human antibody, with a ceiling value of $286,117.10.
Place of performance is Frederick, Maryland. The ultimate completion date is April 8, 2022. The order is priced on a cost-plus-fixed-fee basis with no set-aside.
Service Contract Inventory reporting shows $9 thousand invoiced in FY2021 (76 contractor hours at $121.48/hr) and $97 thousand invoiced in FY2022 (65 contractor hours at $1,486.77/hr). Sri International self-performed all reported labor with no subcontractors.
Quick answers
Who was awarded contract 75N91021F00001?
75N91021F00001 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on April 9, 2021.
How much is contract 75N91021F00001 worth?
The government has obligated $106,343 on 75N91021F00001. Its potential value, with all options, is $286,117.
Is contract 75N91021F00001 an order under another contract?
Yes. 75N91021F00001 is a delivery order under HHSN261201600017I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract 75N91021F00001 competed?
The extent of competition for 75N91021F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award